Endotoxin depresses hepatic cytochrome P450-mediated drug metabolism in women

British Journal of Clinical Pharmacology

Volumn 43, Issue 6, 1997, Pages 627-632

  Shedlofsky, S I ^a,b   Israel, B C ^c,d   Tosheva, R ^a   Blouin, R A ^c  

^a LEXINGTON VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c University of Kentucky   (United States)

^d ClinTrials Research   (United States)

Author keywords

Antipyrine; Cytochrome P450; Drug metabolism; Endotoxin; Gender; Hexobarbitone; Inflammation; Theophylline

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; CYTOCHROME P450; ENDOTOXIN; HEXOBARBITAL; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PHENAZONE; THEOPHYLLINE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PHASE RESPONSE; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG CLEARANCE; DRUG METABOLISM; FEMALE; GENDER; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SEX DIFFERENCE;

EID: 0030834106     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.00603.x     Document Type: Article

References (46)

1. Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA, and The Methylprednisolone Severe Sepsis Study Group. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317: 653-658.
2. Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parrillo JE. Endotoxemia in human septic shock. Chest 1991; 99: 169-175.
3. Shedlofsky SI, Blouin RA, McClain CJ, Wermeling DL. Analysis of medications administered to patients with sepsis syndrome. Hepatology 1994; 20: 398A. [Abstr].
4. Gorodischer RJ, Krasner JJ, McDevitt JP, Nolan JP, Yaffee SJ. Hepatic microsomal drug metabolism after administration of endotoxin in rats. Biochem Pharmacol 1976; 25: 351-353.
5. Williams JF, Lowitt S, Szentivanyi A. Endotoxin depression of hepatic mixed function oxidase system in C3H/HeJ and C3H/HeN mice. Immunopharmacol 1980; 2: 285-291.
6. Stanley LA, Adams DJ, Lindsay R, Meehan RR, Liao W, Wolf CR. Potentiation and suppression of mouse liver cytochrome P-450 isozymes during the acute-phase response induced by bacterial endotoxin. Eur J Biochem 1988; 174: 31-36.
7. Shedlofsky SI, Swim AT, Robinson JM, Gallicchio VS, Cohen DA, McClain CJ. Interleukin-1 (IL-1) depresses cytochrome P-450 levels and activities in mice. Life Sci 1987; 40: 2331-2336.
8. Morgan ET. Suppression of constitutive cytochrome P-450 gene expression in livers of rats undergoing an acute phase response to endotoxin. Mol Pharmacol 1989; 36: 699-707.
9. Ghezzi P, Saccardo B, Villa P, Rossi V, Bianchi M, Dinarello C. Role of interleukin-1 in the depression of liver drug metabolism by endotoxin. Infec Immun 1986; 54: 837-840.
10. Ghezzi P, Saccardo B, Bianchi M. Recombinant tumor necrosis factor depresses cytochrome P-450-dependent microsomal drug metabolism in mice. Biochem Biophys Res Comm 1986; 136: 316-321.
11. Bertini R, Bianchi M, Villa P, Ghezzi P. Depression of liver drug metabolism and increase in plasma fibrinogen by interleukin-1 and tumor necrosis factor: A comparison with lymphotoxin and interferon. Int J Immunopharmacol 1988; 10: 525-530.
12. Wright K, Morgan ET. Regulation of cytochrome P-450IIC12 expression by interleukin-1a, interleukin-6, and dexamethasone. Mol Pharmacol 1991; 39: 468-474.
13. Nadin L, Butler A, Farrell G, Murray M. Pretranslational down-regulation of CYP2C11 and 3A2 in male rat liver by TNFa. Gastroenterology 1995; 109: 198-205.
14. Chen YL, Florentin I, Batt AM, Ferrari L, Giroud JP, Chauvelot-Moachon L. Effects of interleukin-6 on cytochrome P450-dependent mixed function oxidases in the rat. Biochem Pharmacol 1992; 44: 137-148.
15. Shedlofsky SI, Israel BC, McClain CJ, Hill DB, Blouin RA: Endotoxin administration in humans inhibits hepatic P450-mediatied drug metabolism. J Clin Invest 1994; 94: 2209-2214.
16. Schellens JHM, VanDerWart JHF, Danhof M, VanDerVelde EA, Breimer DD. Relationship between the metabolism of antipyrine, hexobarbitone and theophylline in man as assessed by a 'cocktail' approach. Br J Clin Pharmacol 1988; 26: 373-384.
17. Schellens JHM, Janssens AR, VanDerWart JHF, VanDerVelde EA, Breimer DD. Relationship between the metabolism of antipyrine, hexobarbital and theophylline in patients with liver disease as assessed by a 'cocktail' approach. Eur J Clin Invest 1989; 19: 472-479.
18. Schmucker DL, Woodhouse KW, Wang RK, Wynne H, James OF, McManus M, Kremers P. Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clin Pharmacol Ther 1990; 48: 365-374.
19. Bonate PL. Gender-related differences in xenobiotic metabolism. J Clin Pharmocol 1991; 31: 684-690.
20. Fletcher CV, Acosta EP, Strykowski JM. Gender differences in human pharmacokinetics and pharmacodynamics. J Adol Hlth 1994; 15: 619-629.
21. Shapiro BH, Agrawal AK, Pampori NA. Gender differences in drug metabolism regulated by growth hormone. Int J Biochem Cell Biol 1995; 27: 9-20.
22. George J, Byth K, Farrell GC. Age but not gender selectively affects expression of individual chytochrome P450 proteins in human liver. Biochem Pharmacol 1995; 50: 727-730.
23. Urdal P, Burch SM, Landaas S, et al. Rapid immunometric measurement of C-reactive protein in whole blood. Clin Chem 1992; 38: 580-584.
24. Gaetke LM, McClain CJ, Talwalker RT, Shedlofsky SI. Effects of endotoxin on zinc metabolism in human volunteers. Am J Physiol 1997; (in press).
25. Israel BC, Blouin RA, McIntyre W, Shedlofsky SI. Effects of interferon-α monotherapy on hepatic drug metabolism in cancer patients. Br J Clin Pharmacol 1993; 36: 229-235.
26. Elin RJ, Vesell ES, Wolff SM. Effects of etiocholanolone-induced fever on plasma antipyrine half-lives and metabolic clearance. Clin Pharmacol Ther 1975; 17: 447-457.
27. Shedlofsky SI, Kortas DY, Israel BC, Ma L, McClain CJ, Blouin RA. Women volunteers given endotoxin as a model of sepsis have less inhibition than men of P450-mediated drug metabolism. Hepatology 1994; 20: 186A [Abstr].
28. Rosner B. In Fundamentals of Biostatistics, 4th Edition, Duxbury Press, Boston, p. 279, 1995.
29. Bolton S. Pharmaceutical Statistics: Practical and Clinical Applications. Marcel Dekker Inc., New York. 1990; 496-498.
30. Brockmoller J, Roots I. Assessment of liver metabolic function. Clin Pharmacokinet 1994; 27: 216-248.
31. Ha HR, Chen J, Freiburhaus A, Follath F. Metabolism of theophylline by cDNA-expressed human P-450s. Br J Clin Pharmacol 1995; 39: 321-326.
32. Engel G, Hofmann U, Heidemann H, Cosme J, Eichelbaum M. Antipyrine as aprobe for human oxidative drug metabolism. Clin Pharmacol Ther 1996; 59: 613-623.
33. Abdel-Razzak Z, Loyer P, Fautrel A, et al. Cytokines down-regulate expression of major P-450 enzymes in adult human hepatocytes in culture. Mol Pharmacol 1993; 44: 707-715.
34. Abdel-Razzak Z, Corcos L, Fautrel A, et al. TGF-β1 down-regulates basal and polycyclic aromatic hydrocarbon-induced P-450 1A1 and1A2 in adult human hepatocytes in culture. Mol Pharmacol 1994; 46: 1100-1110.
35. Muntane-Relat J, Ourlin J, Domergue J, Maurel P. Differential effects of cytokines on inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture. Hepatology 1995; 22: 1143-1153.
36. Teunissen MNE, Srivastava AK, Breimer DD. Influence of sex and oral contraceptive steroids on antipyrine metabolite formation. Clin Pharmacol Ther 1982; 32: 240-246.
37. Relling MV, Lin JS, Avers GD, Evans WE. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 1992; 52: 643-658.
38. Catteau A, Bechtel YC, Poisson N, Bechtel PR. A population and family study of CYP1A2 using caffeine urinary metabolites. J Clin Pharmacol 1995; 47: 423-430.
39. Nafzinger AN, Bertino JS. Sex-related differences in theophylline pharmacokinetics. Eur J Clin Pharmacol 1989; 37: 97-100.
40. Jennings TS, Nafziger AN, Davidson L, Bertino JS. Gender differences in hepatic induction and inhibition of theophylline pharmacokinetics and metabolism. J Lab Clin Med 1993; 122: 208-216.
41. Bruguerolle B, Toumi M, Faraj F, Vervloet D, Razzouk H. Influence of the menstrual cycle on theophylline pharmacokinetics in asthmatics. Eur J Clin Pharmacol 1990; 39: 59-61.
42. Hooper W, Qing MS. The influence of age and gender on the stereoselective metabolism and pharmacokinetics of mephobarbital in humans. Clin Pharmacol Ther 1990; 48: 633-640.
43. Morgan ET. Down-regulation of multiple cytochrome P450 gene products by inflammatory mediators in vivo: Independence from the hypothalamo-pituitary axis. Biochem Pharmacol 1993; 45: 415-419.
44. Elin RJ, Wolff SM, McAdam KPWJ, Chedid L, Audibert F, Bernard C, Oberling F. Properties of reference Escherichia coli Endtoxin and its phthalylated derivative in humans. J Infect Dis 1981; 144: 329-336.
45. Jeevanandam M, Ramias L, Shamos RF, Schiller WR. Decreased growth hormone levels in the catabolic phase of severe injury. Surgery 1992; 111: 495-502.
46. Li ZG, Davis VA, Brooks PM. Effect of gonadal steroids on the production of IL-1 and IL-6 by blood mononuclear cells in vitro. Clin Exp Rheum 1993; 11: 157-162.